Antibody-Conjugates for Targeting of Tumours Expressing Trop-2
Summary
USPTO published patent application US20260108620A1 covering antibody-conjugate compounds structured to target Trop-2-expressing tumours. Six inventors are named, including Maria Antonia Wijdeven, Jorge Merijn Mathieu Verkade, Jorin Hoogenboom, Sander Sebastiaan van Berkel, Floris Louis van Delft, and Petrus Josephus Jacobus Maria van de Sande. The application was filed on August 7, 2025, and published April 23, 2026, specifying therapeutic payloads including taxanes, anthracyclines, camptothecins, maytansinoids, and pyrrolobenzodiazepine dimers.
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108620A1 for antibody-conjugates structured with a Trop-2-targeting antibody and various cytotoxic payloads designed to improve therapeutic index. The application claims conjugates with payloads selected from taxanes, anthracyclines, camptothecins, maytansinoids, pyrrolobenzodiazepine dimers, radioisotopes, and kinase inhibitors.
Competitors in the antibody-drug conjugate (ADC) space, particularly those developing therapies targeting Trop-2, should review this application for potential overlap with their own intellectual property portfolios. The broad payload list suggests wide claim coverage that could affect freedom-to-operate analyses for ADC programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2
Application US20260108620A1 Kind: A1 Apr 23, 2026
Inventors
Maria Antonia Wijdeven, Jorge Merijn Mathieu Verkade, Jorin Hoogenboom, Sander Sebastiaan van Berkel, Floris Louis van Delft, Petrus Josephus Jacobus Maria van de Sande
Abstract
The present invention concerns antibody-conjugate having general structure (2): wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.
CPC Classifications
A61K 47/6889 A61K 47/6803 A61K 47/68031 A61K 47/68037 A61K 47/6851
Filing Date
2025-08-07
Application No.
19293866
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.